Thoracic Oncology Laboratory

On the road to discovery.... Diagnostics Development, Molecularly-Targeted Therapeutics

Cancer treatment is rapidly proceeding towards the era of personalized medicine where treatment is based on the distinctive molecular characteristics of a patient's tumor. This knowledge will allow patients to receive novel combinations of therapies that will maximize clinical benefit, more accurately predict disease outcome, and allow patients at the highest risk of relapse to receive the most aggressive treatment.

The Thoracic Oncology Lab is pursuing a variety of strategies to treat and cure lung cancer, mesothelioma and esophageal cancer. These include the investigation of molecular pathways such as Wnt and Hh, the role of inflammation in lung carcinogenesis, isolation of lung cancer stems cells, and the Lung Cancer Systems Genetics Project, An Approach to Individualized Lung Cancer Diagnosis and Therapy. Eventually, these efforts will have a major impact on these diseases.

DSC_0082 - Copy

Click to Enlarge

Recent Publications

Hung MS, Xu Z, Chen Y, Smith E, Mao JH, Hsieh D, Lin YC, Yang CT, Jablons DM, You L
Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model.
International journal of oncology, Nov-01-2013; 435: 1517-22.  Epub 2013 Sep 04.
Fang LT, Lee S, Choi H, Kim HK, Jew G, Kang HC, Chen L, Jablons D, Kim IJ
Comprehensive genomic analyses of a metastatic colon cancer to the lung by whole exome sequencing and gene expression analysis.
International journal of oncology, Oct-25-2013; [Epub ahead of print].
Xi Y, Wei Y, Sennino B, Ulsamer A, Kwan I, Brumwell AN, Tan K, Aghi MK, McDonald DM, Jablons DM, Chapman HA
Identification of pY654-β-catenin as a critical co-factor in hypoxia-inducible factor-1α signaling and tumor responses to hypoxia.
Oncogene, Oct-17-2013; 3242: 5048-57.  Epub 2012 Dec 17.
Ganesan AP, Johansson M, Ruffell B, Beltran A, Lau J, Jablons DM, Coussens LM
Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma.
Journal of immunology (Baltimore, Md. : 1950), Aug-15-2013; 1914: 2009-17.  Epub 2013 Jul 12.
Zhang S, Long H, Yang YL, Wang Y, Hsieh D, Li W, Au A, Stoppler HJ, Xu Z, Jablons DM, You L
Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells.
Journal of cellular and molecular medicine, Jul-01-2013; 177: 854-62.  Epub 2013 May 8.
Kratz JR, Tham PT, Mulvihill MS, Ziaei F, Ray MR, Hurst JW, Segal MR, Berryman DM, Chu W, He B, Jablons DM, Mann MJ
Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer.
Diagnostic molecular pathology : the American journal of surgical pathology, part B, Jun-01-2013; 222: 65-9.
Bosco-Clément G, Zhang F, Chen Z, Zhou HM, Li H, Mikami I, Hirata T, Yagui-Beltran A, Lui N, Do HT, Cheng T, Tseng HH, Choi H, Fang LT, Kim IJ, Yue D, Wang C, Zheng Q, Fujii N, Mann M, Jablons DM, He B
Targeting Gli transcription activation by small molecule suppresses tumor growth.
Oncogene, May-20-2013; [Epub ahead of print].
Mulvihill MS, Kratz JR, Pham P, Jablons DM, He B
The role of stem cells in airway repair: implications for the origins of lung cancer.
Chinese journal of cancer, Feb-01-2013; 322: 71-4.  Epub 2012 Nov 1.
Zhang Y, He J, Zhang F, Li H, Yue D, Wang C, Jablons DM, He B, Lui N
SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma.
Journal of experimental & clinical cancer research : CR, [epublish] 32: 7.
Li H, Lui N, Cheng T, Tseng HH, Yue D, Giroux-Leprieur E, Do HT, Sheng Q, Jin JQ, Luh TW, Jablons DM, He B
Gli as a novel therapeutic target in malignant pleural mesothelioma.
PloS one, 83: e57346.
Kim IJ, Quigley D, To MD, Pham P, Lin K, Jo B, Jen KY, Raz D, Kim J, Mao JH, Jablons D, Balmain A
Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas.
Nature communications, 4: 1701.
View all Publications »